Why the study?
Does PET imaging with 18F-NaF and 18F-FDG improve the early detection and evaluation of atherosclerosis?
Does PET imaging with 18F-NaF and 18F-FDG improve the early detection and evaluation of atherosclerosis?
18F-NaF and 18F-FDG PET imaging show promise as molecular probes for the early detection of atherosclerosis and assessment of cardiovascular risk.
May support 18F-NaF PET research for atherosclerosis risk; leaves open clinical adoption pending prospective trials.
The early detection of atherosclerotic disease is vital to the effective prevention and management of life-threatening cardiovascular events such as myocardial infarctions and cerebrovascular accidents. Given the potential for positron emission tomography (PET) to visualize atherosclerosis earlier in the disease process than anatomic imaging modalities such as computed tomography (CT), this application of PET imaging has been the focus of intense scientific inquiry. Although 18 F-FDG has historically been the most widely studied PET radiotracer in this domain, there is a growing body of evidence that 18 F-NaF holds significant diagnostic and prognostic value as well. In this article, we review the existing literature on the application of 18 F-FDG and 18 F-NaF as PET probes in atherosclerosis and present the findings of original animal and human studies that have examined how well 18 F-NaF uptake correlates with vascular calcification and cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
McKenney‐Drake et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: